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Defining the frequency of human 
papillomavirus and polyomavirus 
infection in urothelial bladder 
tumours
Matthew A. Llewellyn  1, Naheema S. Gordon1, Ben Abbotts1, Nicholas D. James1, 
Maurice P. Zeegers2,3, K. K. Cheng  4, Andrew Macdonald5, Sally Roberts1, Joanna L. Parish1, 
Douglas G. Ward1 & Richard T. Bryan1
Given the contradictory nature of the literature regarding the role of human papillomaviruses and 
polyomaviruses in the pathogenesis of urothelial bladder cancer (UBC), we sought to investigate the 
frequency of their involvement in a large cohort of primary UBCs. DNA was extracted from 689 fresh-
frozen UBC tissues and screened for the presence of high-risk human papillomavirus (HPV) types 16 
and 18 and BKV/JCV genomic DNA by qPCR. In positive cases, viral identity was confirmed by Sanger 
sequencing and viral gene expression was analysed by RT-PCR or immunohistochemistry. All 689 
UBCs were negative for HPV18. One UBC from a female patient with areas of squamous differentiation 
was positive for HPV16. The qPCR data indicated variable levels of polyomavirus in 49 UBCs. In the 
UBCs with low Cts we were able to confirm that 23 were BKV and 6 were JCV by Sanger sequencing. 
Polyomavirus large T antigen expression was low but detectable in 70% of the sequencing-confirmed 
polyomavirus positive samples. Thus, in United Kingdom patients, the presence of HPV DNA sequences 
is extremely rare in UBC (<1% of cases). Polyomavirus DNA (predominantly BKV) is more common in 
UBC, but still only detectable in 7% of cases and in many of these cases at low copy number. We have 
performed the largest virus screening to date in UBC, finding that HPV16, HPV18 and HPyV are unlikely 
to be common causative agents in UBC.
Bladder cancer is estimated to be the 9th most common cancer worldwide1. Over 90% of bladder tumours are 
classed as urothelial bladder carcinomas (UBCs), with 75–80% presenting at non-muscle-invasive (NMIBC) 
stages and the remainder presenting at muscle-invasive (MIBC) and metastatic stages2. Recent sequencing studies 
have done much to unravel the enormous genomic complexity in UBC3,4; however, this explosion of knowledge 
has not yet led to the effective application of targeted therapies or a complete understanding of what causes the 
genomic aberrations that initiate and drive UBC. Risk factors which increase the chance of developing bladder 
cancer include (but are not limited to) age, being male, smoking, occupational exposure to aromatic amines, 
polycyclic hydrocarbons or heavy metals and ionising radiation5. Additionally, chronic inflammation such as that 
caused by the parasite Schistosoma haematobium is a risk factor although usually resulting in squamous cell rather 
than urothelial carcinoma5.
It is estimated that 15% of human cancers are caused by infectious agents6. Examples include liver cancer 
(commonly caused by hepatitis B and C viruses), cervical and head and neck cancers (caused by human pap-
illomaviruses, HPVs), and nasopharyngeal carcinoma and Hodgkin’s and Burkitt’s lymphomas (caused by 
Epstein-Barr virus, EBV). Although bladder cancer is not widely considered to be a virus-driven cancer, multiple 
studies have investigated the relationship between oncogenic viruses and UBC: more than 50 studies on HPV 
1Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, 
Birmingham, B15 2TT, UK. 2NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht 
University, Maastricht, Netherlands. 3CAPHRI Care and Public Health Research Institute, Maastricht University, 
Maastricht, Netherlands. 4Institute of Applied Health Research, College of Medical and Dental Sciences, University 
of Birmingham, Birmingham, B15 2TT, UK. 5School of Molecular and Cellular Biology, Faculty of Biological Sciences 
and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK. Correspondence and 
requests for materials should be addressed to R.T.B. (email: r.t.bryan@bham.ac.uk)
Received: 29 December 2017
Accepted: 9 July 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIentIFIC RepoRts |  (2018) 8:11290  | DOI:10.1038/s41598-018-29438-y
and UBC have failed to come to a consensus. Other potentially oncogenic viruses such as EBV and human poly-
omaviruses (HPyVs) have received less attention. In 2013, Lawrence et al.7 reported that the mutational signature 
of UBC is similar to that of two HPV-associated cancers: cervix and head and neck. In 2014 the TCGA detected 
viral DNA in 6% of the UBCs sequenced8. This included three cases of cytomegalovirus, two of HPV16, one of BK 
polyomavirus (BKV), and one of herpesvirus 6B. Viral transcripts were detected in the BKV positive tumour and 
one of the HPV16 positive tumours. In these 2 cases, BKV and HPV16 sequences were integrated into GRB14 and 
BCL2L1, indicating that viruses might play a role in a small percentage of UBCs. We sought to clarify the role of 
HPVs and HPyVs in the United Kingdom UBC population.
We have used qPCR to screen DNA extracted from the primary UBCs of 689 patients recruited to the West 
Midlands Bladder Cancer Prognosis Programme (BCPP)9 between 2005 and 2011 for the presence of HPV16, 
HPV18 and HPyVs. This is the largest such screening to date, and the results emphatically support the literature 
which finds HPV infection to be an extremely rare event in UBC. Our results also support the notion that HPyV 
can be found in a small proportion of bladder cancers (7%), and find evidence for viral gene expression in a pro-
portion of these. Further investigations are required to determine whether HPyV is a bona fide causative factor 
in some UBCs.
Methods
Patient samples and DNA extraction. Patient specimens were collected as part of the Bladder Cancer 
Prognosis Programme (BCPP)9. Immunosuppressed patients were excluded from entering BCPP. All patients 
gave written informed consent to participate in BCPP, and the work described here was conducted with UK 
research ethics approval (ref: 06/MRE04/65), and sponsored by the University of Birmingham (BCPP protocol 
ref: RG_05-088). Hence, all methods were carried out in accordance with the relevant UK guidelines and regu-
lations. Patients were enrolled on the basis of initial cystoscopic findings suggestive of primary UBC. All UBC 
patients were newly-diagnosed and had not received treatment. Tissues were collected at TURBT and stored at 
−80 °C. Tissue specimens (25 mg) were macerated and DNA extracted using the DNeasy Blood and Tissue kit 
(Qiagen). DNA was quantitated using a Qubit (ThermoFisher).
qPCR. HPV16 and HPV18 were assayed in a multiplex qPCR using primers and probes for HPV16 E6, 
HPV18 E7 and GAPDH (Sigma). Primer and probe sequences were exactly as described in ref.10 and were orig-
inally designed to detect only HPV16 or HPV18. All primer and probe sequences are shown in Table S1 and all 
Ct values are shown in Table S2 (Supplemental Information). All qPCRs were carried out in a volume of 20 µl 
using 10 ng genomic DNA, with primers at 400 nM and probes at 250 nM using TaqMan Universal Master Mix 
II, no UNG (Applied Biosystems #4440040) using an Applied Biosystems 7500 Fast Real-Time PCR System. 
The PCR program was 50 °C for 2 min, 95 °C for 10 mins, followed by 45 cycles of 95 °C for 15 s and 55 °C for 
1 min. Patient samples were randomly assigned to 11 PCR plates and each plate also contained positive and 
negative controls, each in triplicate: DNA extracted from UM-SCC-47 cervical cancer cells (HPV16 positive), 
DNA extracted from HeLa cervical cancer cells (HPV18 positive), DNA extracted from UM-SCC-40 cells (HPV 
negative) and water blanks. The assay was validated by analysing serial dilutions of HeLa or UM-SCC-47 cell line 
DNA in UM-SCC-40 cell line DNA (Supplemental Fig. S1). As the assay did not discriminate between HPV16 
and HPV18, positive cases were subsequently identified as HPV16 or HPV18 by running separate HPV16 and 
HPV18 PCRs. PCR products also had their size checked by agarose gel electrophoresis and their identity con-
firmed by Sanger sequencing.
The qPCR assay for BKV and JCV was adapted from Elfaitouri et al.11 and used a single degenerate probe 
and primer pair plus GAPDH primers and probe (Sigma). All other assay parameters were exactly as described 
above. The assay utilises a conserved region of the VP2 gene and BKV- or JCV-positive tumours with VP2 dele-
tions would not be detected. The assay was validated using pBSSK(II)+ plasmids containing BKV and JCV 
VP2 sequences (Dundee Cell Products) as shown in Supplemental Fig. S2. To eliminate the risk of sample con-
tamination with the plasmids, the plasmids were only purchased after all samples had been screened. To deter-
mine which virus had been detected in bladder tissues, the PCR products were subjected to electrophoresis and 
the PCR product excised and Sanger sequenced (Eurofins). Primer, probe and plasmid sequences are shown 
in Table S1. Confirmatory end-point PCRs used 10 ng genomic DNA (0.5 µM primers, sequences as shown in 
Table S1), Phusion High-Fidelity Mastermix (Thermo Scientific, USA) and gel electrophoresis. The PCR program 
was 98 °C for 3 min followed by 35 cycles of 98 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s.
RT-PCR. RNA from frozen specimens and cell lines was extracted using the RNeasy mini kit (Qiagen, 
Germany) and cDNA synthesised from 0.5 µg RNA with the Superscript Vilo™ kit (Thermo Scientific) accord-
ing to the manufacturer’s protocol (final volume cDNA = 20 µl). GAPDH PCR was used to verify the success of 
cDNA synthesis. The presence of viral genes in the cDNA was analysed by PCR using 1 µl cDNA (0.5 µM primers, 
sequences as shown in Table S1), Phusion High-Fidelity Mastermix (Thermo Scientific, USA) and gel electropho-
resis. The PCR program was 98 °C for 3 min followed by 35 cycles of 98 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s.
Large T antigen immunohistochemistry. De-paraffinisation and antigen retrieval was performed using 
the citrate buffer/microwave method, before incubating overnight with 2 µg/ml mouse monoclonal antibody 
against SV40 large T antigen (Abcam, ab16879, cross-reactive with BKV)12. Sections were completed using a 
secondary antibody (ImmPRESS HRP universal detection kit) and visualised using the ImmPACT DAB perox-
idase (Vector laboratory, UK). BKV infected/non-infected primary renal proximal tubular epithelial cells were 
used as controls for antibody specificity (Supplemental Fig. S5). The operator was blinded as to the identity of the 
samples.
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Results
HPV. Using the combined assay for HPV16/HPV18 sequences to analyse the DNA extracted from fresh frozen 
tissue specimens, we obtained a positive result for HPV (Ct = 24) in 1 out of the 689 UBCs tested (0.1%) (Table 1) 
whereas the internal control (GAPDH) was positive in all cases. The HPV positive sample was from a female 
patient aged 51 and the pathology report noted squamous elements within the tumour. This sample was subse-
quently assayed for HPV16 and 18 sequences separately and only gave a positive PCR result with HPV16 primers. 
RT-PCR was used to determine if the HPV16 oncogenes E6 and E7 were expressed in the HPV16 positive UBC: 
both E6 and E7 mRNAs were detectable (Fig. 1).
Polyomavirus. More than 90% of the samples were negative or below the limit of detection for HPyV. 
However, HPyV was detected with a Ct of <31 in 20 samples, and a further 27 samples showed weak/borderline 
positivity (Ct 31–33). Based on standard curves generated with VP2 gene containing plasmids we estimate that 
2 of the most positive UBCs had >100 viral copies per cell, another 3 UBCs had 10–100 copies per cell with the 
remaining 15 positive cases having 1–10 copies per cell. The 27 weak/borderline cases had a viral copy number <1 
copy per cell. All of these samples were subjected to a confirmatory PCR and the products separated by agarose 
gel electrophoresis. When a sample produced a visible band of the expected size it was excised, the DNA eluted 
and analysed by Sanger sequencing; in 29 cases a readable HPyV sequence was obtained. BKV was present in 23 
samples (mean Ct = 28.2) and JCV present in 6 samples (mean Ct = 29.9). The presence of multiple regions of the 
BKV genome was confirmed in a subset of samples using primers specific for BKV VP1, VP2 and Small T antigen 
(Fig. 2). The age and gender of the HPyV positive cases were similar to the characteristics of the whole patient 
cohort: median age of 72.5 years old and 26 patients were male and 3 female. Table 1 shows the distribution of 
the 29 sequencing-confirmed HPyV positive tumours across stages and grades of disease (4 × G1, 9 × G2 and 
16 × G3 cases positive). There were no significant differences between the frequency of HPyV detection in differ-
ent stages or grades of disease (p > 0.05).
Large T antigen expression was analysed by immunohistochemistry in FFPE tissue from 13 of the UBCs 
which screened positive for HPyV DNA, 8 borderline positive UBCs and 6 negative UBCs. In all cases there was 
no large T antigen detected in the vast majority of cells. However, nuclear expression was detected in a few scat-
tered cells or patches of cells in 9 of the 13 positive cases, 2 of the 8 borderline cases and 1 of the 6 negative cases. 
Representative images are shown in Fig. 3. Whilst the correlation between qPCR and IHC data lends support to 
low-level expression of large T antigen in some of these bladder tumours, we were able to extract reasonable qual-
ity RNA (RIN > 7) from several specimens but large T antigen expression was not detectable by qPCR.
Discussion
We have screened 689 bladder tumours for the presence of HPV16, HPV18, BKV and JCV. We find a complete 
absence of HPV18 in all tumours, and the presence of HPV16 in only one UBC. Whilst expression of the HPV16 
oncogenes was detectable in this sample, the presence of high levels of HPV16 in urothelial carcinomas of the 
bladder is clearly very rare and as this patient was female we cannot completely rule out that the tumour might 
have originated in the cervix13. Due to limits of analytical sensitivity our data cannot rule out the presence of 
extremely low levels of HPV16 or HPV18 in bladder tumours, but it is clear that the majority of bladder tumours 
do not contain HPV16 or HPV18. Thus, for HPV16 or HPV18 to play a significant role in bladder cancer, we have 
to envisage the scenario that the virus initiates an oncogenic effect which persists after the virus is eliminated. 
Group Number
Grade G1/
G2/G3 Age
Gender 
M/F
HPV16 
positive
HPV18 
positive
BKV 
positive
JCV 
positive
pTis 4 0/0/4 72 4/0 0 0 0 0
pTa 303 95/158/50 70 234/69 0 0 8 3
pT1 187 3/42/142 72 158/29 0 0 8 3
pT2+ 174 0/6/168 72 134/40 1 0 4 0
Stage or grade 
unknown 21 NA 73 11/10 0 0 3 0
Table 1. Patient characteristics and viral screening results. Data shown are the number of individuals in each 
patient group, grade (1/2/3), median age (yrs), gender (male/female) and the number of individuals positive for 
HPV16, HPV18 and HPyV.
Figure 1. RT-PCR for HPV16 E6 and E7 gene expression. The gel shows PCR products from cDNA synthesised 
from the HPV positive UBC, a negative DNA control and, for validation purposes, HeLa and UM-SCC-47 cells.
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It should, however, be noted that historic infections have been suggested as a cause of APOBEC enzyme activation 
leading to the APOBEC mutation signature seen in UBCs7.
Our data is in line with the lack of detection of HPV DNA in 109 UBCs analysed by PCR in 201514, in 375 
UBCs analysed by PCR in 201613, and only three HPV16 and three HPV18 positive cases out of 412 UBCs 
reported by TCGA4. Indeed, our study is the largest single screening of UBCs for HPV16 and 18 to date and 
strongly supports the hypothesis that these high-risk HPV types are not, or exceedingly rarely, contributors to 
UBC pathogenesis. Contrarily, so many earlier studies reported moderate to high frequencies of HPV infection 
in UBC that a recent meta-analysis concluded that 17% of bladder tumours are positive for HPVs, predominantly 
HPV16 and HPV1815. The reasons for this disparity are unclear but may, at least partially, be due to geographical 
variation with higher HPV incidence in UBC in Asia and Africa compared to Europe and North America15.
We detected HPyV DNA at varying levels in approximately 4% of the tissue samples analysed. Thirty of these 
yielded sufficient PCR product for Sanger sequencing and 23 were identified as BKV and 6 as JCV. Our rate of 
HPyV positivity is lower than the 14 out of 30 cases (44%) reported by Fioriti et al.16, but more in line with the 4 
Figure 2. End-point PCR confirmation of polyomavirus qPCR results. The figure shows an agarose gel of PCR 
products generated using BKV or human GAPDH primers and DNA extracted from tumours. + indicates 
BKV positive tumours (Cts of 17.6, 22.5, 25.3 and 26.2 respectively, left to right) and − indicates BKV negative 
(Ct > 35). The numbers on the left indicate the ladder sizes (bp). The predicted sizes for the 5 amplicons are 250, 
281, 161, 164 and 269 bp respectively. The 5 PCRs were run separately (in parallel) and analysed on separate gels.
Figure 3. Large T antigen immunohistochemistry. Data are shown for 4 tumours. (A) Grade 3 MIBC, Ct 17.6, 
(B) grade 2 pTa, Ct 21.1, (C): grade 2 pTa, Ct 29.2, (D) grade 3 MIBC, qPCR negative.
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out of 30 cases (13%) that Panagiotakis et al. reported17, and the 4 out of 73 cases (5%) that Rollison reported18. 
Fioriti also reported that, as we have confirmed, BKV is more prevalent than JCV in UBC. Interestingly, Fioriti 
found no HPyV in bladder tissue from 20 control subjects and Panagiotakis found no HPyV in 30 adjacent nor-
mal tissues, the higher frequency in tumours suggesting either that the virus contributes to tumour development, 
or that the tumour is more susceptible to infection. In our HPyV positive cases, although expression levels were 
low, immunohistochemistry suggested large T antigen expression in 70% of the HPyV positive UBCs, limited to 
a few scattered nuclei.
One limitation of our study is that the large T antigen immunohistochemistry data could not be corroborated 
at the mRNA level. Whilst it is possible that the epitope is expressed but that primer binding sites have been lost 
during integration, the immunohistochemistry data should be considered preliminary until HPyV gene expres-
sion is confirmed by another technique e.g. RNA-Seq. Using genomic methods TCGA detected one case of BKV 
in 412 UBCs4,8. In this UBC the BKV genome was integrated into the human genome and large T antigen mRNA 
was expressed4,8,19. Of the 412 UBCs studied by TCGA, only 136 underwent whole genome sequencing (which 
should detect BKV DNA), whilst the majority had both exome and RNA sequencing. Exome sequencing library 
preparation would not be expected to capture viral sequences, and RNA-Seq will only detect viruses if the read 
depth is sufficient to detect viral mRNA: our data showing that large T antigen expression is limited to a few scat-
tered nuclei suggest that this might not always be the case. Thus, TCGA data may underestimate the frequency of 
BKV DNA in UBC, but does concur with our data that high levels of BKV gene expression occur extremely rarely 
in UBC. A second limitation of our study is that there is a continuum of HPyV “positivity” in the qPCR data and 
it is difficult to differentiate between very low levels and a complete absence of virus. Thus, whilst we report that 
up to 7% of UBCs may be positive for HPyV, we have only unequivocally demonstrated that 4% of UBCs contain 
HPyV DNA sequences. It may be worth considering alternative primers or even a probe-based capture and next 
generation sequencing approach to improve assay sensitivity and specificity in the future.
Conclusions
We have performed the largest screening to date of HPV16, HPV18 and HPyV in bladder cancer. We found a 
low prevalence of HPV16 and HPV18 (<1%) and HPyV (7%). Although our results cannot completely exclude 
a causative role for these viruses in the pathogenesis of UBC, it is clear that high-levels of virus are not persistent 
driving factors in UBC.
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